USFDA grants EIR to Cadila Healthcare
DSIJ Intelligence / 29 Aug 2017
As part of the successful closure of audit, Zydus Cadila’s formulation manufacturing facility at Pharma SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA.
As part of the successful closure of audit, Zydus Cadila’s formulation manufacturing facility at Pharma SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA.
Meanwhile, stock dipped in trade marginally by 0.21% at Rs 500 per share on the BSE. On the NSE the stock attracted a total traded volume of 9,07,144 shares and a traded value of Rs 4,513.22 lakhs. The company has had a return on equity of 30.36% for the last three years and has been maintaining a healthy dividend payout ratio of 19.70%.
The BSE Healthcare index was trading lower by 0.47% at the 13,233 level with Sun Pharmaceutical Industries being a major contributor to the index’s losses. Sun Pharma is trading lower by 0.97% at Rs 487.95 per share.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.